Holen Sie sich die Stockscreener-App
28.45
1.25%
-0.36
Handel nachbörslich:
28.44
-0.010
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$28.81
Offen:
$28.58
24-Stunden-Volumen:
23.53M
Relative Volume:
0.57
Marktkapitalisierung:
$162.16B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
21.81
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
+1.75%
1M Leistung:
+11.96%
6M Leistung:
+6.87%
1J Leistung:
+15.93%
1-Tages-Spanne:
$28.38
$28.69
1-Wochen-Bereich:
$27.64
$29.21
52-Wochen-Spanne:
$23.58
$29.21
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
28.45 | 158.39B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Advances PF-07248144 With Key Drug-Interaction Study Completion - TipRanks
Pfizer: Patient Investors Will Be Rewarded (NYSE:PFE) - Seeking Alpha
Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy. - Barron's
Mitsubishi UFJ Trust & Banking Corp Grows Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Pfizer stock holds gains after Q2 2026 earnings beat and guidance raise - Ad-hoc-news.de
Global Retirement Partners LLC Makes New $4.34 Million Investment in Pfizer Inc. $PFE - MarketBeat
Bank of New York Mellon Corp Has $1.39 Billion Position in Pfizer Inc. $PFE - MarketBeat
What Is New for Pfizer (NYSE:PFE) Across Its Oncology Pipeline? - Kalkine Media
Pfizer (PFE) Rides MRNA Cancer Optimism On A Valuation That Still Looks Modest - simplywall.st
PCF-Pfizer Visiting Professorship Program 2026 for Precision Medicine in Prostate Cancer Care - Oncodaily
Pfizer (NYSE:PFE) Shares Down 1.5%Should You Sell? - MarketBeat
Pfizer Stock's Next Chapter Might Be Hiding in Plain Sight - Trefis
Quant MF raises Pfizer stake with Rs 131 cr purchase; Pari Washington buys over 2% in Amrutanjan Health Care - TradingView
Pfizer Stock Is A Race Between New Drugs And Old Patents - Trefis
Pfizer’s Ibrance Real-World Breast Cancer Study Wraps Up: What Investors Should Watch Next - TipRanks
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead - 24/7 Wall St.
Pfizer stock hits a fresh 52-week high as Q2 2026 earnings beat and guidance lift support the rally. - Ad-hoc-news.de
KBC Group NV Sells 144,649 Shares of Pfizer Inc. $PFE - MarketBeat
Janney Montgomery Scott LLC Has $58.14 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Why Is Pfizer (NYSE:PFE) Settling Thousands of Legal Claims? - Kalkine Media
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Pfizer (PFE) Breaks to a 52-Week High at $28.24, Clearing the April Peak - 24/7 Wall St.
Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims - simplywall.st
Why Pfizer (PFE) Stock Is Trading Up Today - Yahoo Finance
Pfizer (NYSE:PFE) Shares Up 3.7%Still a Buy? - MarketBeat
A Look at Pfizer Inc (PFE) After 3.6% Gain -- GF Value $26.53 vs Price $28.24 - GuruFocus
PFE Stock Quote Price and Forecast - CNN
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? - 24/7 Wall St.
Pfizer Inc Stock (PFE) Moved Up by 3.96% on Aug 19: What Signal Does It Send? - TradingKey
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions - Benzinga
Pfizer Stock Rises Wednesday: What's Going On? - Benzinga
Pfizer's Obesity Push: Can Berobenatide Take Market Share? - Yahoo Finance
Pfizer Inc (PFE): A Closer Look Behind a 68 GF Score - GuruFocus
Insider Watch: 3 CEOs Betting Millions on Their Own Stocks - TradingView
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool
Pfizer Shares Gain 1.4% as Insider Acquisition Worth $3 Million Counters Reports of Fund Sales - TechStock²
Pfizer stock holds steady as investors weigh Q2 earnings beat and pipeline updates - Ad-hoc-news.de
Pfizer Inc. $PFE Shares Sold by Heritage Investors Management Corp - MarketBeat
TD Asset Management Inc Has $94.56 Million Stake in Pfizer Inc. $PFE - MarketBeat
Leuthold Group LLC Makes New Investment in Pfizer Inc. $PFE - MarketBeat
111 Capital Takes $3.71 Million Position in Pfizer Inc. $PFE - MarketBeat
Pfizer (NYSE:PFE) Trading Up 1.6%Here's Why - MarketBeat
Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows - Yahoo Finance
Pfizer Pick of the Week at Smart Insider Following CEO's First Share Purchase - marketscreener.com
Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff - Seeking Alpha
Pfizer Inc. $PFE Holdings Increased by Willis Investment Counsel - MarketBeat
University of Texas Texas AM Investment Management Co. Invests $3.97 Million in Pfizer Inc. $PFE - MarketBeat
Cornerstone Capital Inc. Grows Position in Pfizer Inc. $PFE - MarketBeat
Can Pfizer (NYSE:PFE) Pipeline Wins Offset Non-Cash Impairment Charges? - Kalkine Media
Albert Bourla Bought 9.6% More Shares In Pfizer - simplywall.st
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pfizer Inc-Aktie (PFE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 05 '26 |
Sale |
25.40 |
3,278 |
83,261 |
28,611 |
| BLAYLOCK RONALD E | Director |
Aug 05 '26 |
Buy |
25.46 |
39,231 |
998,821 |
66,938 |
| Buckley Mortimer J | Director |
Aug 05 '26 |
Buy |
25.52 |
37,632 |
960,369 |
37,632 |
| DAMICO JENNIFER B. | SVP & Controller |
Jun 09 '26 |
Sale |
25.70 |
2,000 |
51,400 |
31,397 |
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):